Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AML Hub continues to enhance global knowledge of acute myeloid leukemia throughout 2021

07/19/2021 | 03:58am EDT

The AML Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), has continued to promote significant developments in the treatment and research of acute myeloid leukemia (AML) throughout Quarter 2 of 2021. The AML Hub provides up-to-date, unbiased material for healthcare professionals within the AML community, worldwide.

Input from the hub's executive steering committee and scientific advisory board allows the AML Hub to gauge the latest content demands and to deliver material of the highest value. On May 25, 2021, the AML Hub held a virtual steering committee meeting, which highlighted the achievements of the AML Hub, as well as the unmet clinical needs in the AML setting and how to address them. The success of the virtual format of the meeting further emphasized the versatility and resilience of the AML Hub and its affiliates.

Speaking about the success of the hub's activity, Mia Hill, IME director at Scientific Education Support, said:

"In the second quarter of 2021, the AML Hub continued to successfully navigate the virtual climate, remotely covering the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the Acute Leukemia Forum (ALF) 2021, the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, and the European Hematology Association (EHA) 2021 Virtual Congress. The AML Hub provided a combination of live and on-demand social media coverage of key sessions and conducted interviews with experts in the field of AML.

For the first time, in order to help navigate the exciting content being presented at the EHA2021 Virtual Congress, members of the AML Hub Executive Steering Committee kindly provided their insights into the top abstracts to look out for in AML. We compiled both the clinical content and the disease biology sessions in the form of a downloadable resource, including links to view the abstracts."

The hub has faced several challenges throughout 2021, and reflecting on these challenges, Mia Neve said:

"The SARS-CoV-2 pandemic has challenged healthcare services and individuals worldwide, especially patients with hematologic malignancies. The AML Hub is working hard to bring you the latest information regarding COVID-19 and its implications in the AML setting: a summary of the guidelines on COVID-19 vaccination for hematopoietic stem cell transplant patients has been published, based on expert recommendations presented during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

The AML Hub owes thanks to its supporters -Roche Genentech, AbbVie, Amgen, Novartis, Bristol Myers Squibb, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Gamida Cell, and Takeda -without whom the work would not be possible. In Quarter 2, the AML Hub was delighted to welcome Syndax as a supporter and would like to extend a special thanks for their support going forward."


For more information on the AML Hub, please visit aml-hub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.

About acute myeloid leukemia (AML)

Leukemia is cancer of the white blood cells. Acute leukemia means that the cancer progresses quickly and aggressively, and usually requires immediate treatment.

Acute leukemia is classified according to the type of white blood cells affected. There are two main types of white blood cells:

- lymphocytes-cells that fight viral infections.

- myeloid cells-cells that have a variety of functions, such as fighting bacterial infections, defending the body against parasites, and preventing the spread of tissue damage.

AML is an aggressive cancer of the myeloid cells.

About the AML Hub

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in AML. Our aim is to enhance knowledge on AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The AML Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the AML Hub supports HCPs worldwide.

The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

AML Hub supporters

Funding for our hubs are made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert Steering Committee. All content is independent, and the educational supporters are allowed no influence on the content.

- Genentech

- Roche

- AbbVie

- Amgen

- Novartis

- Bristol Myers Squibb

- Syndax

- Janssen Oncology

- Jazz Pharmaceuticals

- Gamida Cell

- Takeda

If you are interested in becoming an AML supporter, please contact secretariat@scientificeducationsupport.com

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'KNOW' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, MPN Hub, and MDS Hub.

About the European LeukemiaNet

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SME s across Europe to form a network promoting cooperative research for curing leukemia.

Distributed by https://pressat.co.uk/


(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.80% 60.63 Delayed Quote.-2.26%
GAMIDA CELL LTD. 2.69% 4.2 Delayed Quote.-51.25%
JAZZ PHARMACEUTICALS PLC 3.82% 134.5 Delayed Quote.-18.51%
09/20BRISTOL MYERS SQUIBB : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Mela..
09/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
09/20Bristol Myers Squibb Announces FDA Accepts for Priority Review Biologics License Applic..
09/20Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
09/17BRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Treating Gastr..
09/17BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
09/17Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo with Chemotherapy for Pa..
09/17Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers
09/16Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Sinc..
09/16BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combination
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 378 M - -
Net income 2021 6 495 M - -
Net Debt 2021 28 289 M - -
P/E ratio 2021 21,0x
Yield 2021 3,24%
Capitalization 135 B 135 B -
EV / Sales 2021 3,51x
EV / Sales 2022 3,16x
Nbr of Employees 30 250
Free-Float 76,0%
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 60,63 $
Average target price 75,39 $
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291